These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9514194)
1. Antithrombotic action of TA-993, a new 1,5-benzothiazepine derivative, in a canine model of femoral arterial thrombosis. Kaburaki M; Doi H; Narita H; Odawara A; Yasoshima A; Murata S J Cardiovasc Pharmacol; 1998 Mar; 31(3):470-7. PubMed ID: 9514194 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of 1,5-benzothiazepine derivatives having a l-cis and d-cis configuration in anesthetized dogs. Kaburaki M; Inoue H; Doi H; Yasuhara M; Narita H Biol Pharm Bull; 1998 Jan; 21(1):50-5. PubMed ID: 9477168 [TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. Narita H; Kaburaki M; Doi H; Yasoshima A; Murata S Jpn J Pharmacol; 1995 Aug; 68(4):397-404. PubMed ID: 8531414 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effect of a new 1,5-benzothiazepine derivative TA-993 in anesthetized dogs. Kaburaki M; Narita H; Yabana H; Karasawa T; Doi H; Murata S J Cardiovasc Pharmacol; 1998 Feb; 31(2):240-7. PubMed ID: 9475265 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation. Odawara A; Kikkawa K; Katoh M; Toryu H; Shimazaki T; Sasaki Y Circ Res; 1996 Apr; 78(4):643-9. PubMed ID: 8635222 [TBL] [Abstract][Full Text] [Related]
6. The mechanism of the increasing action of TA-993, a new 1,5- benzothiazepine derivative, on limb blood flow in anesthetized dogs: selective suppression of sympathetic nerve activity. Kaburaki M; Yabana H; Doi H; Nagata K; Narita H; Murata S J Pharmacol Exp Ther; 1999 Mar; 288(3):1167-73. PubMed ID: 10027855 [TBL] [Abstract][Full Text] [Related]
7. Protective effect of TA-993, a novel therapeutic agent for peripheral circulatory insufficiency, on skeletal muscle fatigue in a rat model of hindlimb ischemia. Doi H; Kaburaki M; Inoue H; Suzumura K; Narita H Jpn J Pharmacol; 2000 May; 83(1):73-81. PubMed ID: 10887943 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects. Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790 [TBL] [Abstract][Full Text] [Related]
9. Occlusive thrombosis in the femoral artery of the rabbit: a pharmacological model for evaluating antiplatelet and anticoagulant agents. Sugidachi A; Asai F; Tani Y; Hosokawa T; Koike H Blood Coagul Fibrinolysis; 1996 Jan; 7(1):57-64. PubMed ID: 8845464 [TBL] [Abstract][Full Text] [Related]
10. Vascular actions of TA 3090, a novel analog of diltiazem: interaction with endothelium-dependent relaxation in canine femoral and coronary arteries. Rubanyi G; Iqbal A; Schwartz A; Vanhoutte PM J Pharmacol Exp Ther; 1991 Nov; 259(2):639-42. PubMed ID: 1941612 [TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. Shimazawa M; Takiguchi Y; Umemura K; Kondo K; Nakashima M Eur J Pharmacol; 1997 Jun; 328(2-3):183-9. PubMed ID: 9218700 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007 [TBL] [Abstract][Full Text] [Related]
15. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist. Mousa SA; Forsythe M; Wityak J; Bozarth J; Mu DX J Cardiovasc Pharmacol; 1998 Mar; 31(3):441-8. PubMed ID: 9514190 [TBL] [Abstract][Full Text] [Related]
16. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of a new 1,5-benzothiazepine calcium antagonist in anesthetized dogs. Murata S; Kikkawa K; Yabana H; Nagao T Arzneimittelforschung; 1988 Apr; 38(4):521-5. PubMed ID: 3401267 [TBL] [Abstract][Full Text] [Related]
18. Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury. Beaughard M; Brasset M; John G; Massingham R J Cardiovasc Pharmacol; 1995 Oct; 26(4):577-83. PubMed ID: 8569218 [TBL] [Abstract][Full Text] [Related]
19. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728. Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524 [TBL] [Abstract][Full Text] [Related]
20. Effect of diltiazem on experimental coronary artery thrombosis in dogs. Schumacher WA; Lucchesi BR Pharmacology; 1990; 41(1):16-23. PubMed ID: 2236203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]